Literature DB >> 4137739

Kinetic studies on phosphorylation of 5-azacytidine with the purified uridine-cytidine kinase from calf thymus.

T Lee, M Karon, R L Momparler.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1974        PMID： 4137739

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  8 in total

Review 1.  Therapy with azanucleosides for myelodysplastic syndromes.

Authors:  Alfonso Quintás-Cardama; Fabio P S Santos; Guillermo Garcia-Manero
Journal:  Nat Rev Clin Oncol       Date:  2010-06-15       Impact factor: 66.675

2.  RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-azacytidine activity in acute myeloid leukemia.

Authors:  Josephine Aimiuwu; Hongyan Wang; Ping Chen; Zhiliang Xie; Jiang Wang; Shujun Liu; Rebecca Klisovic; Alice Mims; William Blum; Guido Marcucci; Kenneth K Chan
Journal:  Blood       Date:  2012-04-19       Impact factor: 22.113

Review 3.  DNA methylation as a target for drug design.

Authors:  C M Bender; J M Zingg; P A Jones
Journal:  Pharm Res       Date:  1998-02       Impact factor: 4.200

4.  Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.

Authors:  Gautam Borthakur; Xuelin Huang; Hagop Kantarjian; Stefan Faderl; Farhad Ravandi; Alessandra Ferrajoli; Ritva Torma; Gail Morris; Donald Berry; Jean-Pierre Issa
Journal:  Leuk Lymphoma       Date:  2010-01

5.  DNA methyltransferase inhibitors improve the effect of chemotherapeutic agents in SW48 and HT-29 colorectal cancer cells.

Authors:  Sylwia Flis; Agnieszka Gnyszka; Krzysztof Flis
Journal:  PLoS One       Date:  2014-03-27       Impact factor: 3.240

6.  AID downregulation is a novel function of the DNMT inhibitor 5-aza-deoxycytidine.

Authors:  Chiou-Tsun Tsai; Pei-Ming Yang; Ting-Rong Chern; Shu-Hui Chuang; Jung-Hsin Lin; Lars Klemm; Markus Müschen; Ching-Chow Chen
Journal:  Oncotarget       Date:  2014-01-15

7.  Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine.

Authors:  A Valencia; E Masala; A Rossi; A Martino; A Sanna; F Buchi; F Canzian; D Cilloni; V Gaidano; M T Voso; O Kosmider; M Fontenay; A Gozzini; A Bosi; V Santini
Journal:  Leukemia       Date:  2013-11-06       Impact factor: 11.528

8.  Using antagonistic pleiotropy to design a chemotherapy-induced evolutionary trap to target drug resistance in cancer.

Authors:  Kevin H Lin; Justine C Rutter; Abigail Xie; Bryann Pardieu; Emily T Winn; Reinaldo Dal Bello; Antoine Forget; Raphael Itzykson; Yeong-Ran Ahn; Ziwei Dai; Raiyan T Sobhan; Gray R Anderson; Katherine R Singleton; Amy E Decker; Peter S Winter; Jason W Locasale; Lorin Crawford; Alexandre Puissant; Kris C Wood
Journal:  Nat Genet       Date:  2020-03-16       Impact factor: 38.330
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.